Q1 2023 EPS Estimates for Atea Pharmaceuticals, Inc. Increased by SVB Leerink (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […]

Related Keywords

,Morgan Stanley ,Geode Capital Management ,Atea Pharmaceuticals Trading ,Blackrock Inc ,Nasdaq ,Vanguard Group Inc ,News Ratings For Atea Pharmaceuticals Daily ,Atea Pharmaceuticals ,Atea Pharmaceuticals Inc ,Hermes Inc ,Institutional Trading Of Atea Pharmaceuticals ,Get Rating ,Atea Pharmaceutical ,Street Corp ,Capital Management ,Atea Pharmaceuticals Daily ,Nasdaq Avir ,Tavir ,Medical ,Earnings Estimates ,Svb Leerink Llc ,